Scott C. Woller, MD

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, Scott C. Woller, MD sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).

2 total trials 1 currently recruiting 1 completed later-stage tilt upper half by trial count

Scott C. Woller, MD: 2 sponsored US clinical trials, 1 recruiting.

Scott C. Woller, MD sponsors 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 1 completed. 1 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Antiphospholipid Syndrome, with 1 trials.

Mid-pack sponsor footprint

Scott C. Woller, MD is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Where Scott C. Woller, MD enrollment is open (later-stage tilt)

1 recruiting of 2 indexed (50% open); 1 completed (50%).

Phase mix: 1 late (III/IV) vs 0 early (I/II) (later-stage heavy).

Top condition: Antiphospholipid Syndrome (1 trial), 5 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Scott C. Woller, MD: open-pipeline peers nationwide

Peers matched on 2 registered trials and 50% open enrollment, not the therapeutic-area sidebar.

Scott C. Woller, MD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 1.522.533.544.5 0%20%40%60% Total trials Recruiting share Scott C. Woller, MD1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO Health3ive Labs60 Degrees Pharmaceuticals7 Hills PharmaAbcentra
Scott C. Woller, MD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Scott C. Woller, MD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 2 trials (± recruiting share)

Sponsors near 50% open enrollment (± trial volume)

What to do with this Scott C. Woller, MD page

2 registered trials is a research-attention snapshot, not an endorsement of Scott C. Woller, MD or any single study.

  • 1 of Scott C. Woller, MD's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Antiphospholipid Syndrome is the condition Scott C. Woller, MD studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Antiphospholipid Syndrome trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Scott C. Woller, MD pipeline card: 2 registered trials from official public datasets.Report a data error.